Ann Intern Med

1. LAINE C, Turner BJ, Qaseem A, Moyer DV, et al
   Vaccines: Decision Making Amid Conflicting Recommendations.
   Ann Intern Med. 2025 Sep 16. doi: 10.7326/ANNALS-25-04054.
   

   >> Share

   
   

   
   BMJ

2. IACOBUCCI G
   mRNA vaccines and cancer: Experts warn of misinformation as Malhotra row goes mainstream.
   BMJ. 2025;390:r1934.
   

   >> Share

   
   

   
   J Virol

3. PAPPAS C, Brock N, Belser JA, Kieran TJ, et al
   Identification of clinical and virological correlates associated with influenza A candidate vaccine virus (CVV) attenuation in a ferret model.
   J Virol. 2025 Sep 17:e0102325. doi: 10.1128/jvi.01023.
   

   >> Share

   
   
4. ZHANG C, Zhou Y-C, Song W-Y, Liu X-X, et al
   Rationally designed self-assembled peptide nanofibers provoke robust humoral immunity against nervous necrosis virus.
   J Virol. 2025;99:e0031925.
   

   >> Share

   
   

   
   MMWR Morb Mortal Wkly Rep

5. O'HALLORAN A, Habeck JW, Gilmer M, Threlkel R, et al
   Influenza-Associated Hospitalizations During a High Severity Season - Influenza Hospitalization Surveillance Network, United States, 2024-25 Influenza Season.
   MMWR Morb Mortal Wkly Rep. 2025;74:529-537.
   

   >> Share

   
   

   
   PLoS One

6. POKU CA, Owusu GA, Gyamfuah P, Addae G, et al
   Determinants of vaccination uptake among pregnant women in Kumasi: A multi-centre cross-sectional study.
   PLoS One. 2025;20:e0332425.
   

   >> Share

   
   
7. MARFOH K, Samba A, Okyere E, Fattah AZ, et al
   Post-vaccination SARS-CoV-2 infections among healthcare workers in a tertiary hospital in Ghana.
   PLoS One. 2025;20:e0331971.
   

   >> Share

   
   

   
   Proc Natl Acad Sci U S A

8. SWINGLE KL, Hamilton AG, Han X, Liao KC, et al
   Circular RNA lipid nanoparticle vaccine against SARS-CoV-2.
   Proc Natl Acad Sci U S A. 2025;122:e2505718122.
   

   >> Share

   
   

   
   Vaccine

9. SSALI A, Nalubega P, Namugumya R, Kyohere M, et al
   Pregnant and breastfeeding women concerns during a group B Streptococcus phase ll clinical trial: A qualitative study in Kampala, Uganda.
   Vaccine. 2025;62:127592.
   

   >> Share

   
   
10. PROCIANOY GS, Silveira RC, Procianoy RS
    Impact of the May 2024 floods on childhood immunization coverage in Rio Grande do Sul, Brazil.
    Vaccine. 2025;62:127573.
    

    >> Share

    
    
11. ENGLISH S, Fedosyuk S, Orliacq F, Tem V, et al
    Rabies glycoprotein engineering for improved stability and expression.
    Vaccine. 2025;62:127541.
    

    >> Share

    
    
12. SALOMAO MDG, de Almeida Leitao Curimbaba C, Braga PE, Franca JID, et al
    Long-term efficacy and immune response of CoronaVac in Brazilian health care workers: Insights from PROFISCOV unblinded trial.
    Vaccine. 2025;62:127527.
    

    >> Share

    
    
13. VAN DER WEG W, von Kreijfelt G, Davidson L, Zwaveling J, et al
    Strengthening spontaneous reporting-based signal detection during a pandemic with cases from electronic health records using a natural language processing tool.
    Vaccine. 2025;62:127549.
    

    >> Share

    
    
14. SHIBUYA Y
    Culture filtrate proteins from Bacillus Calmette-Guerin.
    Vaccine. 2025;62:127486.
    

    >> Share

    
    
15. RICHARDSON M, Daneman N, Miller FA, Sander B, et al
    Moving from intervention management to disease management for Clostridioides difficile infection: an economic evaluation exploring the impact of a systems approach to health technology assessment.
    Vaccine. 2025;62:127512.
    

    >> Share

    
    
16. BROAD J, Letley L, Adair G, Walker J, et al
    An England-wide survey on attitudes towards antenatal and infant immunisation against respiratory syncytial virus amongst pregnant and post-partum women.
    Vaccine. 2025;62:127482.
    

    >> Share

    
    
17. ARIYARAJAH A, Crowcroft NS, Brown KA, Wang J, et al
    Measles seroprevalence among individuals serologically tested in Ontario, Canada.
    Vaccine. 2025;62:127446.
    

    >> Share

    
    
18. WAGNER SB, Rincon M, Keen KE, Hawk GS, et al
    SARS-CoV-2 breakthrough infection during pregnancy preferentially elicits IgG4 response and enhanced placental-transfer.
    Vaccine. 2025;62:127476.
    

    >> Share

    
    
19. SANO K, Miyakawa K, Kato H, Kimura Y, et al
    Neutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC.
    Vaccine. 2025;62:127472.
    

    >> Share

    
    
20. BAUSSANO I, Tenet V, Baghdasarova K, Harutyunyan Z, et al
    HPV burden in Armenia among unvaccinated women: a series of cross-sectional population-based prevalence surveys.
    Vaccine. 2025;62:127405.
    

    >> Share

    
    
21. WANG J, Zhao W, Bai S, Zhang A, et al
    Different patterns of antimicrobial non-susceptibility of the nasopharyngeal carriage of Streptococcus pneumoniae in areas with high and low levels of PCV13 coverage.
    Vaccine. 2025;62:127455.
    

    >> Share

    
    
22. SCHMITT MM, Rossler A, Netzl A, Knabl L, et al
    Exposure to two antigenically distinct SARS-CoV-2 variants broadens neutralization patterns.
    Vaccine. 2025;62:127459.
    

    >> Share

    
    
23. PIERCE SR, Shi H, Caetano C, Prots DA, et al
    Self-amplifying mRNA expressing COBRA hemagglutinin elicits long-lasting, broadly reactive antibodies against seasonal influenza A viruses.
    Vaccine. 2025;62:127449.
    

    >> Share

    
    
24. SHEN Y, Sung MH, Ge Y, Chen Y, et al
    Predicting influenza vaccine-elicited antibody responses with practical point systems.
    Vaccine. 2025;64:127737.
    

    >> Share

    
    
25. PIAL RH, Capeding MR, Tadesse BT, Excler JL, et al
    Longevity of immune-response provided by at least one dose of vi-DT vaccine 5 years after vaccination among healthy Filipino adults and children.
    Vaccine. 2025;64:127751.
    

    >> Share

    
    
26. INOUE S, Fuji K
    The mutual cyclical influence of internet information and vaccination intention on post-dissemination vaccination: A longitudinal study during the availability period of COVID-19 booster shots.
    Vaccine. 2025;64:127741.
    

    >> Share

    
    
27. HAMONIC G, Pastural E, Arora S, Lew J, et al
    Safety and immunogenicity of COVAC-2, a Sepivac SWE adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.
    Vaccine. 2025;64:127748.
    

    >> Share

    
    
28. RAMACHANDRAN V, Tangney S, Gedlinske A, Askelson NM, et al
    Pneumococcal vaccination knowledge, attitudes, and practices among surveyed U.S. adults aged 19-64 years at increased risk for pneumococcal disease.
    Vaccine. 2025;64:127739.
    

    >> Share

    
    
29. ODAGIRI T, Yoshino N, Sasaki Y, Ishikawa S, et al
    Polymyxin B as a novel mucosal adjuvant for the intranasal whole inactivated influenza vaccine.
    Vaccine. 2025;64:127750.
    

    >> Share

    
    
30. TURJEMAN A, Shochat T, Drozdinsky G, Leibovici L, et al
    Disparities and temporal trends in pneumococcal vaccination uptake among older adults in the Israeli population: A population-based retrospective cohort study.
    Vaccine. 2025;64:127765.
    

    >> Share

    
    
31. SEGEL JE, Luan P, Ramos ML, Zaorsky NG, et al
    Drivers of HPV vaccination rates among adolescent dependents in the military health system.
    Vaccine. 2025;64:127753.
    

    >> Share

    
    
32. VAN BEEK LF, He X, Koks MS, van der Gaast-de Jongh CE, et al
    Comparing the immunogenicity of intradermal and intramuscular vaccination of elderly with BNT162b2 XBB.1.5: An equivalent dose study.
    Vaccine. 2025;64:127749.
    

    >> Share

    
    
33. MANAQUIN R, Desmoulin A, Luong Nguyen LB, Kornblum D, et al
    Acceptance of chikungunya vaccination: a rapid survey in Reunion island during an epidemic.
    Vaccine. 2025;64:127720.
    

    >> Share

    
    
34. LANE A, Quach HQ, Ovsyannikova IG, Kennedy RB, et al
    High-resolution antibody dynamics following influenza vaccination reveal predominantly weak responses as well as infrequent but durable immunity across the 2014-2022 seasons.
    Vaccine. 2025 Sep 12:127677. doi: 10.1016/j.vaccine.2025.127677.
    

    >> Share

    
    
35. SCHUE JL, Fesshaye B, Miller ES, Singh P, et al
    Examining the role of influence and trust in information sources on the COVID-19 vaccine decision-making process for pregnant and postpartum women in Brazil, Ghana, Kenya, and Pakistan: A mixed methods study.
    Vaccine. 2025 Sep 12:127721. doi: 10.1016/j.vaccine.2025.127721.
    

    >> Share

    
    
36. HUANG W, Xu M, Diao Z, Chen J, et al
    Vaccination coverage by age 24 months among children born in 2020 and 2021 in China, during the COVID-19 pandemic: A study based on the national immunization information system.
    Vaccine. 2025;64:127717.
    

    >> Share

    
    
37. KANG W, Wang F, Hao Z, Zhang Z, et al
    A follow-up study on the protective efficacy and anamnestic response of recombinant CHO hepatitis B vaccine 26 years after immunization.
    Vaccine. 2025;64:127743.
    

    >> Share

    
    
38. YANG Y, Jin SW, Lee S, Lartey S, et al
    Understanding vaccine willingness in post-COVID America: Key determinants and demographic differences.
    Vaccine. 2025;64:127740.
    

    >> Share

    
    
39. KORVES C, Kulldorff M, Balajee AS, Smith J, et al
    Innovative use of self-controlled methods for the evaluation of waning effectiveness of the COVID-19 monovalent third dose: comparison with a test-negative design.
    Vaccine. 2025;63:127658.
    

    >> Share

    
    
40. LOUTH J, Holland A, Chum C, Morgan L, et al
    Understanding the immunity gap for serogroup B invasive meningococcal disease due to non-pharmaceutical interventions during the Covid-19 pandemic.
    Vaccine. 2025;63:127647.
    

    >> Share

    
    
41. GOLLUB EL, Myszkowski N, Xi M, Boyraz G, et al
    Correlates of higher trust in public health officials: results from a representative cohort of private university undergraduates.
    Vaccine. 2025;63:127610.
    

    >> Share

    
    
42. ZHAO Y, Li G, Li Q, Shi H, et al
    Identification and evaluation of cross-protection efficiency of the conserved antigens of Salmonella Enteritidis.
    Vaccine. 2025;62:127622.
    

    >> Share

    
    
43. STIMPSON JP, Tamirisa K, Morenz AM, Adhikari EH, et al
    Trust typologies and HPV awareness in the U.S.: a latent class analysis.
    Vaccine. 2025;62:127606.
    

    >> Share

    
    
44. WU X, Xing J, Tang X, Sheng X, et al
    Temporal transcriptome analysis of head kidney revealed protective cellular immunity in flounder (Paralichthys olivaceus) immunized with inactivated Edwardsiella piscicida.
    Vaccine. 2025;62:127613.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share